The new research results will help determine whether the existing new crown vaccine needs to be adjusted to resist Omi Keron. The WHO stated that any decision to change the composition of the vaccine requires careful consideration, especially considering that the delta variant is the main cause of the current epidemic, and the existing vaccines provide adequate protection.
WHO experts said that urgent research on Omi Keron has begun to understand the effectiveness of the current new crown vaccine against Omi Keron, and the answer may be obtained in the next few days.
During the epidemic, Dr. Ana-Maria Henao-Restrepo, who co-led the WHO’s vaccine and innovative R&D blueprint plan, said that about 450 researchers around the world have already started to isolate highly mutated variants from patient specimens and put them in the laboratory. Culture, verify its genome sequence, and establish a method to detect this variant in plasma samples:
Researchers hope to find the answer within a few days, but I think that pressure should not be put on (them) to give results within three days, it should be said that it will be possible in the next two weeks.
As the Ome Keron virus spreads globally, the current market is worried that the immune protection produced by the existing new crown vaccine is not enough to prevent re-infection. The new research results will help determine whether the existing new crown vaccine needs to be adjusted to resist Omi Keron.
Including Modena and BioNTech, a number of mainstream vaccine manufacturers have previously stated that the company’s current new crown vaccine may not be sufficient to protect against Omi Keron virus and may need to develop new vaccines to deal with it.
Henao-Restrepo said that any decision to change the composition of the vaccine needs to be carefully considered, especially considering that the delta variant is the main cause of the current epidemic, and the existing vaccines provide adequate protection. Nevertheless, some vaccine manufacturers have begun to prepare for fine-tuning the vaccine.
According to Wall Street reports, there are more than 30 mutations in the spike protein of the virus, which may render existing vaccines ineffective. Because the spike protein is not only the key used by the virus to open the door of our body cells, but also the target of most vaccines.
“We may not be able to keep it out of individual countries”
Ome Keron virus is currently spreading widely overseas. According to data from the European Center for Disease Control and Prevention (ECDC), as of this Friday, 109 confirmed cases of Omikeron have been found across the European Economic Area (EU plus Norway, Iceland and Liechtenstein).
In the United States, there are a total of 10 confirmed cases, 2 of which have no travel records abroad.This indicates that the spread of the mutant virus has begun in the country.
WHO spokesperson Christian Lindmeier said in an interview on Friday that there have been no reports of deaths related to Omi Keron. The World Health Organization urges countries not to panic, but to prepare for its possible spread.
Lindmeier pointed out that the delta virus variant was announced this summer as a variant worthy of attention, and now it has become the main epidemic virus, accounting for more than 90% of the world:
This is how this virus behaves, and we may not be able to keep it out of individual countries.
In the context of the surge in new crown reinfection cases in South Africa, WHO is sending a technical reinforcement team to Gauteng, South Africa, to monitor the Omi Kejon variant and help track the infected.
Agence France-Presse quoted the South African official report on Friday,A total of more than 3 million cases of Omi Keron variant virus have been confirmed in South Africa.In the last 24 hours, 16,000 new cases have been diagnosed.
Risk warning and exemption clause
Market risk, the investment need to be cautious. This article does not constitute personal investment advice, nor does it take into account the specific investment objectives, financial situation or needs of individual users. Users should consider whether any opinions, opinions, or conclusions in this article are consistent with their specific conditions. Invest accordingly at your own risk.